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Abstract 
Background: Group A streptococci (GAS) are the most common bacterial cause of acute pharyngitis and account for 
15–30 % of cases of acute pharyngitis in children and 5–10 % of cases in adults. In this study, a real-time quantitative 
PCR (qPCR) based GAS detection assay in pharyngeal swab specimens was developed.
Methods: The qPCR assay was compared with the gold standard bacterial culture and a rapid antigen detection test 
(RADT) to evaluate its clinical performance in 687 patients. The analytical sensitivity of the assay was 240 cfu/swab. 
Forty-five different potential cross-reacting organisms did not react with the test. Four different laboratories for the 
reproducibility studies were in 100 % (60/60) agreement for the contrived GAS positive and negative swab samples.
Results: The relative sensitivities of the RADT and the qPCR test were 55.9 and 100 %; and the relative specificities 
were 100 and 96.3 %, respectively. Duration of the total assay for 24 samples including pre-analytical processing and 
analysis changed between 42 and 55 min depending on the type of qPCR instrument used. A simple DNA extraction 
method and a low qPCR volume made the developed assay an economical alternative for the GAS detection.
Conclusion: We showed that the developed qPCR test is rapid, cheap, sensitive and specific and therefore can be 
used to replace both antigen detection and culture for diagnosis of acute GAS pharyngitis.
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Background
Acute pharyngitis is a nonspecific symptom that can 
result from a number of viral or bacterial infections. 
Group A streptococci (GAS) are the most common bac-
terial cause of acute pharyngitis and account for 15–30 % 
of cases of acute pharyngitis in children and 5–10  % of 
cases in adults [1]. The cost per case of GAS pharyngi-
tis was estimated to be approximately $205, with about 
half of the costs attributed to nonmedical costs such as 
missed days of work by parents for child care [2].
GAS pharyngitis is usually self-limited and resolves 
without the need for antibiotic treatment [3]; however, 
a minority of patients develop severe complications 
such as scarlet fever and peritonsillar cellulitis, as well 
as immune-mediated complications, including post-
streptococcal glomerulonephritis and acute rheumatic 
fever. Early treatment of GAS pharyngitis with appropri-
ate antibiotics is known to reduce symptom severity and 
duration, decrease transmission of the organism, and 
reduce the risk of acute rheumatic fever [4]. Incidence of 
the rheumatic heart disease changes between 0.03 and 
2.1  % based on the development status of the countries 
[5].
As most pharyngitis is viral in origin, accurate diag-
nosis can reduce the unnecessary use of antibiotics and 
potential development of antibiotic resistance [6, 7]. 
However, accurate diagnosis of GAS pharyngitis is dif-
ficult for a number of reasons. First, diagnosis of GAS 
pharyngitis using clinical signs alone is unreliable due 
to the broad overlap in symptoms between the viral and 
bacterial etiologies [4]; physicians miss up to 50 % of GAS 
pharyngitis cases and identify 20–40 % of non-GAS sore 
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throat cases as requiring antibiotics [8]. Second, many 
children are asymptomatic carriers of GAS, with the 
prevalence of GAS throat carriage estimated at 12 % [9]. 
Third and the most important, the standard procedure 
for laboratory detection of GAS, culture on blood agar, 
typically requires 24–48 h [10], which is problematic for 
physicians to provide the diagnosis on the same day of 
patients office visit.
Value of rapid testing for the GAS pharyngitis diagno-
sis in directing clinical management and reducing unnec-
essary antibiotic prescription has been documented [11, 
12]. The fast diagnosis methods include rapid antigen 
detection tests (RADTs) and nucleic acid-based meth-
odologies. RADTs provide results within minutes, but 
exhibit only 72–90  % sensitivity compared to that of a 
culture [13]. Polymerase chain reaction (PCR) [14, 15], 
real-time quantitative PCR (qPCR) [16, 17] and loop-
mediated isothermal amplification (LAMP) [18, 19] 
based tests for the detection of GAS have been described. 
These tests have high sensitivity (>93 %) and good speci-
ficity (>95  %). The PCR and qPCR based tests have not 
been found wide application due to insufficient clinical 
evaluation [14, 16], high cost [17] and labor intensive 
laboratory work [15]. A LAMP based method, the Illumi-
gene group A Streptococcus assay, has been developed 
by Meridian Bioscience and cleared by the FDA. Henson 
et al. [19] and Anderson et al. [18] evaluated its clinical 
performance and reported that the assay is rapid (<1 h), 
easy to perform and highly sensitive and specific.
Current Infectious Diseases Society of America (IDSA) 
guidelines state that a clinical diagnosis of GAS phar-
yngitis must be confirmed [4]. Reimbursement for the 
culture and the molecular based analyses are 9.12$ and 
48.24$ respectively in USA, which makes the Illumi-gene 
group A Streptococcus assay (28$/test), an economi-
cally feasible tool for diagnosis of GAS pharyngitis (Sales 
Sheet: Illumigene Group A Streptococcus). On the other 
hand, there is no reimbursement for the molecular detec-
tion of GAS pharyngitis in most of the developing coun-
tries due to the very high costs of the tests. Furthermore, 
the clinical signs have been the major diagnostic tools in 
developing countries like Turkey where the cost of anti-
biotic treatment is very low (3–10$). This has resulted 
in considerable social burden [20] and unnecessary anti-
biotic prescriptions in up to 75 % of patients with acute 
tonsillopharyngitis [21] and a total (outpatients and hos-
pital care) antibiotic use of 42.3 defined daily doses/1000 
inhabitants per day (DID) for Turkey which has made 
Turkey the first among 40 countries in Europe in the cal-
culation of unit ranks for antibiotic usage [22].
In this study, we aimed to develop a qPCR based GAS 
detection assay in pharyngeal swab specimens that is as 
rapid as the previous molecular tests, as sensitive and 
specific as the culture test and as economical as the low-
cost antibiotic treatments.
Methods
Study participants and collection of specimens
The study was conducted in accordance with the Dec-
laration of Helsinki and approved by Istanbul Medipol 
University (IMU) Research Ethics Committee. The throat 
swab specimens were collected at IMU Hospital from 687 
patients aged between 5 and 12  years presenting acute 
sore throat over the winter/spring of 2012 and 2013. The 
study population included 356 (51.8  %) female and 331 
(48.2  %) male patients. No restrictions were placed on 
gender, medications or known pharmaceutical therapies.
Two blind samples were collected using the BBL Cul-
tureSwab EZ II—Double Swab (Becton–Dickinson, USA) 
according to the standard methods [4]. One swab was 
used for the RADT and culture and the other was used 
for the qPCR assay. The samples for the culture and anti-
gen tests were transported to Istanbul Medipol Univer-
sity Laboratory at ambient temperature and processed on 
the day of sample collection. The samples for the molecu-
lar analysis were transported to Istanbul Technical Uni-
versity Molecular Biology, Genetics and Biotechnology 
Research Center (ITU MOBGAM) at +2 to 8 °C and ana-
lyzed on the day of sample collection.
Culture and antigen test
The swabs were inoculated on BBL strep selective agar 
(Becton–Dickinson, USA) plates and incubated at 35  °C 
for 16–18 h. Catalase negative colonies with a morphol-
ogy of β-hemolytic streptococcus were transferred to 5 % 
sheep blood agar and subjected to bacitracin, sulfameth-
oxazole–trimethoprim (SXT) susceptibility test, BBL 
DrySlide PYR and BBL Streptocard Enzyme Latex Test 
Kit (Becton–Dickinson, USA) for GAS confirmation.
After inoculation of the SSA plate, the same swab was 
used for evaluation with the Clearview® Strep A Exact II 
Cassette test (Inverness Medical Professional Diagnos-
tics, USA). The procedure was performed according to 
the instructions provided by the manufacturer.
Molecular analyses
The swabs were cut and placed into 1.5  ml microcentri-
fuge tubes containing 400  μl of 0.1  M Tris–HCl pH 8.0. 
The tubes were placed in TSS-2000 turbo thermal shaker 
& heater (Inovia Technology, Turkey), shaken for 20  s at 
3000 rpm, incubated at +95 °C for 10 min and shaken for 
20 s at 3000 rpm. The swabs were removed from the sam-
ple tubes and discarded. The samples were immediately 
used in qPCRs and stored at −20 °C after the qPCR set up.
Two different qPCRs (qPCR-GAS and qPCR-PC) were 
set up by combining 5  μl of the supernatant with 5  μl 
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of two different 2x qPCR master mix in 0.1 ml reaction 
tubes. The qPCR-GAS and qPCR-PC contained prim-
ers targeting Streptococcus pyogenes pyrogenic exotoxin 
B (speB) and Bacillus thermocatenulatus triacylglycerol 
lipase (BTL2) genes respectively. The qPCR-PC also con-
tained BTL2 gene. The qPCR-PC was set up as a posi-
tive control reaction to evaluate inhibitory effect of the 
sample on the DNA amplification. Five microlitre DNase 
free molecular grade water was combined with 5 μl of 2x 
qPCR-GAS master mix as a negative control (qPCR-NC).
Biospeedy EvaGreen Real-Time PCR 2x premix (Bioek-
sen R&D Technologies, Turkey) was used for qPCR. The 
premix contains 12 mg/ml bovine serum albumin (BSA), 
40 mg/ml PEG 400, %0.5 Tween 20, 40 mM Tris–HCl pH 
8.0, 100 mM KCl, 3 mM MgCl2, 0.4 mM dNTP mix, 0.2U 
Hot-Start Taq DNA Polymerase and 0.2x EvaGreen Dye. 
The 2x qPCR-GAS master mix was prepared by adding 
200  nM of the each speB1166-F (5′-AAAGTAGGCGG 
ACATGCCTTTG-3′) and speB1268-R (5′-CAAGACGG 
AAGAAGCCGTCAG-3′) primers to the premix. The 2x 
qPCR-PC master mix was prepared by adding 200  nM 
of the each BTL908-F (5′-CGACGGATACTGCCCGC 
TAC-3′) and BTL1014-R (5′-CCGTTCGGTGGAAAAG 
CTCA-3′) primers and 5 ng of their target BTL2 gene to 
the premix.
QPCR cycling conditions were an initial 3 min at 95 °C 
step, followed by 35 amplification cycles of 95 °C for 5 s 
and 60  °C for 25  s. A melt-curve analysis with a tem-
perature transition rate of 0.5  °C/s was performed from 
60 to 90  °C to determine if only one amplified product 
was generated during qPCR. The qPCR was carried out 
using four different Real-Time PCR system: Biorad CFX 
Connect (Bio-Rad Laboratories, USA), LightCycler 480 
(Roche Applied Science, USA), StepOne Plus (Life Tech-
nologies, USA) and Xxpress (BJS Biotechnologies, UK). 
The samples which had a melting temperature (Tm) of 
qPCR-GAS between 80 and 81 °C and no specific ampli-
fication in qPCR-NC were considered positive. The 
samples that had no specific amplification in the qPCR-
GAS and qPCR-NC were considered negative for GAS. 
Threshold cycle (Ct) of the qPCR-PC was lower than 25 
with a Tm between 80 and 81 °C. The qPCR-PC Ct val-
ues higher than 25 were considered an indicator of PCR 
inhibitor interference.
The amplified DNA fragments in positive qPCR-GAS 
reactions from the tested 687 patients and the contrived 
positive (S. pyogenes ATCC 19615) swab samples were 
purified using High Pure PCR Product Purification Kit 
(Roche Applied Science, USA) and sequenced using the 
ABI prism Big Dye Terminator Cycle Sequencing Ready 
Reaction Kit on an ABI Prism 377 DNA sequencer (Life 
Technologies, USA). The sequences were analyzed in 
Chromas software package version 2.0 (Technelysium, 
Australia) and manually checked for the reading errors. 
The sequences were aligned with S. pyogenes strain 
ATCC 19615 whole genome region from 849512 to 




Twenty replicates of the BBL CultureSwab EZ—Sin-
gle Swab (Becton–Dickinson, USA) were spiked with 
101–104 CFU S. pyogenes ATCC 19615 in 100 μl Buffer1 
(0.1  M Tris–HCl pH 8.0). Following determination of a 
detection limit in a wide range, e.g. between 2 × 102 and 
3 ×  102 CFU, five more dilutions were prepared within 
this range. Limit of detection (LOD) stated a 95 % (19/20) 
probability of obtaining the reference samples positive 
for GAS. S. pyogenes ATCC 49399 and 12344 strains 
were also tested at the determined LOD. Interferences 
of 5 mg/mL mucus and 10 % v/v human saliva in Buffer1 
were tested with contrived positive (ATCC 19615) sam-
ples prepared at the determined LOD. Analytical sensi-
tivity studies were carried out using Biorad CFX Connect 
qPCR instrument.
Analytical specificity
In-Silico PCR with speB1166-F and speB1268-R primers 
was carried out using the Primer Blast tool (http://www.
ncbi.nlm.nih.gov/tools/primer-blast/) to test the cross 
reactivity among all available sequences in DNA data-
bases. 55  bp fragment of Bacillus sp. GL1 unsaturated 
glucuronyl hydrolase gene (AB019619) and 1217 bp frag-
ment of Myxococcus stipitatus DSM 14675 long-chain-
fatty-acid-CoA ligase gene (CP004025) were amplified 
with total mismatches of 7 and 9 bases respectively. 
Myxococcus stipitatus DSM 14675 and chemically syn-
thesized 55 base fragment of the Bacillus sp. GL1 DNA 
(Macrogen Inc., Europe) were included in the analytic 
specifity tests.
The BBL CultureSwab EZ—Single Swab (Becton–Dick-
inson, USA) were spiked with 106 CFU bacterial or fun-
gal organisms in 100  μl Buffer1. 20  ng/μl human DNA, 
20 ng/μl Bacillus sp. GL1 DNA and the following organ-
isms were tested for the cross reactivity:
Acinetobacter baumannii, Aeromonas hydrophila, 
Arcanobacterium haemolyticum, Bordetella bronchisep-
tica, Burkholderia cepacia, Campylobacter jejuni, Can-
dida albicans, Citrobacter freundii, Corynebacterium 
diphtheria, Corynebacterium pseudodiphtheriticum, 
Enterococcus faecalis, Enterococcus faecium, Escherichia 
coli, Haemophilus influenzae, Klebsiella oxytoca, Kleb-
siella pneumoniae, Lactococcus lactis, Legionella pneu-
mophila, Listeria monocytogenes, Moraxella catarrhalis, 
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Morganella morganii, Myxococcus stipitatus, Neisseria 
pharyngis, Neisseria meningitidis, Proteus mirabilis, 
Pseudomonas aeruginosa, Staphylococcus aureus, Staph-
ylococcus epidermidis, Stenotrophomonas maltophilia, 
Streptococcus agalactiae, Streptococcus anginosus, Strep-
tococcus bovis, Streptococcus canis, Streptococcus dysga-
lactiae (subspecies equisimilis), Streptococcus equinus, 
Streptococcus intermedius, Streptococcus mitis, Strepto-
coccus mutans, Streptococcus pneumoniae, Streptococcus 
salivarius, Streptococcus suis, Streptococcus uberis, Strep-
tococcus sp. viridans type.
Reproducibility
Contrived high positive (105 CFU ATCC 19615), positive 
(240 CFU ATCC 19615), low negative (105 CFU non-tar-
get organism mix) and negative (without any organism) 
swab samples were prepared using Buffer1. Five sets 
of blind-coded panels of 12 samples (three replicates of 
the four swab types) were supplied to four independent 
laboratories each having a different qPCR instrument 
(Biorad CFX Connect, LightCycler 480, StepOne Plus 
and Xxpress). Samples were randomly sorted within each 
panel to mask sample identities. Different operators at 
each site performed testing on the same day (intra-assay 
variability) for 5  days (inter-assay variability). Duration 
of the total assay for 12 samples was also measured each 
day.
Statistical analysis
After assessment of normality of data, differences 
between the replicate samples in terms of Ct and Tm 
values were evaluated using the Student’s t test. Analy-
ses were performed using the software MINITAB 17 
(Minitab Ltd., England).
The sample size to show that the developed assay is not 
worse than the culture was calculated based on 5 % non-
inferiority limit as described by Blackwelder [23]. It was 
estimated that “If there is a true 5 % difference between 
the developed assay and the culture, then 375 patients are 
required to be 90  % sure that the upper limit of a one-
sided 95  % confidence interval (or equivalently a 90  % 
two-sided confidence interval) will exclude a difference in 
favour of the standard group of more than 5 %”.
Results
LOD of the qPCR test was 240 CFU/Test for S. pyogenes 
ATCC 19615. The swabs containing 240 CFU S. pyogenes 
ATCC 49399 or 12344 strains also produced positive 
reactions. The qPCRs at the stated LOD were positive 
for all of the replicates with Ct value of 25.9 ±  1.2 and 
a single Tm peak at 80.3  ±  0.2  °C. The qPCR product 
sequences matched 100 % with S. pyogenes strain ATCC 
19615 speB gene.
Human DNA, Bacillus sp. GL1 DNA and the poten-
tial cross-reacting microorganisms did not react with the 
test. Some of the negative control organisms gave a Ct 
value between 30 and 35, but the Tm was not consistent 
with the target amplification (80–81 °C). 5 mg/mL mucus 
and 10 % v/v human saliva did not interfere with the test 
results at the stated LOD. There were no statistically 
important Ct differences between the samples with and 
without interfering substances (t > 2.02, df = 38, p < 0.05).
All of the sites for the reproducibility studies were in 
100  % agreement (60/60) for the contrived positive and 
negative samples. There were no statistically important 
Ct and Tm differences between the positive tests carried 
out in the different qPCR instruments (t > 2.00, df = 58, 
p < 0.05). Biorad CFX Connect, LightCycler 480, StepOne 
Plus and Xxpress produced Tm values of 80.3  ±  0.2, 
80.3  ±  0.1, 80.2  ±  0.2 and 80.2  ±  0.1  °C respectively. 
Duration of the total assay for 24 samples including pre-
analytical processing and analysis was 50  ±  2, 51  ±  3, 
55 ± 3 and 42 ± 3 min for Biorad CFX Connect, Light-
Cycler 480, StepOne Plus and Xxpress respectively.
Table  1 compares the results for the developed qPCR 
method and the RADT, to those of the conventional cul-
ture method that is well known as a gold standard for 
GAS detection [10]. The four different qPCR instruments 
produced the same test results for the clinical perfor-
mance evaluation. The qPCR product sequences from 
the positive 222 throat swabs matched 100 % with S. pyo-
genes strain ATCC 19615 speB gene. PCR inhibition was 
not detected by means of a lack of internal control (BTL2 
gene) amplification for all of the samples.
In no case was a throat swab negative by the qPCR 
method but positive by culture. However, positive results 
occurred by the qPCR method for some samples that 
were negative by culture. All of the discordant results by 
the RADT method versus the results of culture were pos-
itive by culture.
Table 1 Performance characteristics comparison of  the 
developed qPCR method to those of the rapid antigen test 
(RAT) and the gold standard culture method for detection 
of GAS from the 687 throat swabs
Results Culture RAT QPCR
Positive 204 114 222
Negative 483 573 465
Prevalence 29.7 % 16.6 % 32.3 %
Sensitivity 69.4 % 100 %
Specificity 100 % 96.4 %
Positive predictive value 100 % 92.9 %
Negative predictive value 84.3 % 100 %
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Discussion
Sensitivity and specificity of the DNA amplification 
based GAS detection tests have already been reported to 
be 100 and 95 % for PCR [15], 100 and 100 % for qPCR 
[16] and 100 and 98 % for LAMP [18]. The approximate 
times required to complete these tests including pre-ana-
lytical processing and analysis are as follows: PCR, 3–4 h; 
qPCR, 1.5–3 h; LAMP, 50–60 min. We showed that the 
developed qPCR test is rapid (42–55  min), sensitive 
(100 %) and specific (96.4 %) and therefore can be used to 
replace both antigen detection and culture for diagnosis 
of acute GAS pharyngitis. With the speed of the qPCR 
assay, results can be relayed to health care providers and 
patients in less than 2 h after the test is ordered.
The high speed of the developed qPCR test was mainly 
because of the rapid DNA extraction method that can 
be completed in less than 15  min for 24 samples. The 
extraction method did not eliminate the possible PCR 
inhibitors such as collagen [24]. The DNA amplification 
facilitators, betaine and BSA, were included in the qPCRs 
to compensate the possible effects of the inhibitors [25]. 
This application resulted in no PCR inhibition in the clin-
ical performance studies.
In this study, RADT provided the fastest results, but 
exhibited only 69.4 % sensitivity compared to that of cul-
ture. Due to difficulties in the sampling from children, 
the swab used for RADT was first used to inoculate an 
agar plate in the clinical performance evaluation stud-
ies. This is one of the limitations of the study since some 
of the bacterial content might have been removed from 
the swab and affected sensitivity of RADT. The low sen-
sitivity problem of the antigen tests has frequently been 
reported [13]. If RADTs are performed routinely, culture 
must be applied to the all RADT-negative specimens. 
The non-GAS acute pharyngitis accounts for 70–95 % of 
the cases [1] and only 70 % of the true-positive samples 
are expected to be detected using RADTs. If culture is 
performed after RADT, more than 70  % of the patients 
should have a throat culture.
There are no methods defined in the literature to dis-
tinguish GAS carriage from actual streptococcal phar-
yngitis. All the patients in our study had presented with 
acute sore throat and up to 12 % of these may actually be 
carriers [9].
The qPCR product sequences of 18 samples that were 
culture negative but qPCR positive matched with S. pyo-
genes speB gene. Although throat culture was considered 
as the gold standard, the detected GAS DNA may be 
associated with the following: First, some of the patients 
might have taken antibiotics at the time throat swabs 
were taken. This would restrict growth on a culture but 
not the qPCR results. Second, errors of sampling may 
always be an issue. Third, qPCR may be more sensitive 
than standard culture. All of the positive patients by 
qPCR were treated with antibiotics effective against 
GAS, even though the health care providers responsi-
ble for these patients were unaware of the qPCR result. 
Uhl et  al. [17] also reported that all discordant posi-
tive results for the qPCR method versus the results of 
culture were believed to be associated with the disease 
when they evaluated the GAS test results along with the 
medical history recorded by the health care provider. 
On the other hand, the qPCR assay does not distin-
guish between DNA from viable and non-viable organ-
isms. In order to prevent the false positive results, DNA 
from the non-viable GAS can be eliminated via pre-
treatment of the specimens with propidium monoazide 
[26] or DNase-I [27]. Since the specificity of the devel-
oped qPCR test was high enough, we do not recom-
mend application of these pretreatment strategies avoid 
increase in total analysis time and cost.
The simple DNA extraction using only the Tris–HCl 
buffer and the low qPCR volume (10 μl) makes the devel-
oped assay a very economical alternative for GAS detec-
tion. Based on the outcomes of this study, “Republic of 
Turkey Social Security Institution Health Applications 
Notification” has recently been updated and “S. pyogenes 
fast PCR test” was added to the reimbursement list [28]. 
Reimbursement for the S. pyogenes fast PCR test is 1.95$ 
that was calculated based on a testing potential of 2 mil-
lion tests per year.
Conclusion
Our rapid, cheap, sensitive and specific qPCR test can 
replace both antigen detection and culture for diagnosis 
of acute GAS pharyngitis.
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